The marketing authorisation for Fablyn has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Fablyn : EPAR - Summary for the public (PDF/340.06 KB)
First published: 23/03/2009
Last updated: 22/06/2012
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Dr. Friedrich Eberth Arzneimittel GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
27/02/2012 Fablyn - EMEA/H/C/000977 - T/0003
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. A significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1).
When determining the choice of Fablyn or other therapies, including oestrogens, for a postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).